Unity Biotechnology expects cash, cash equivalents to fund operations into 2H21 » 08:0907/3107/31/20
UNITY believes that…
UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the second half of 2021.
Unity Biotechnology to initiate Phase 1 safety study for UBX1325 in 2H20 » 08:0907/3107/31/20
In July 2020, UNITY…
In July 2020, UNITY announced that it has completed Investigational New Drug application -enabling studies with UBX1325, an investigational senolytic, small molecule inhibitor of the anti-apoptotic Bcl-2 family member, Bcl-xL. Assuming clinical sites are able to recruit and retain investigators and study staff and screen and enroll patients during the ongoing COVID-19 pandemic, UNITY expects to initiate a Phase 1 safety study for UBX1325 in the second half of 2020 and obtain initial results from the study in 2021. The overall clinical program is directed at multiple age-related diseases of the eye, such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration.
Unity Biotechnology expects 12-week results from Phase 2 UBX0101 study in Q3 » 08:0807/3107/31/20
In July 2020, UNITY…
In July 2020, UNITY announced that it expects to announce topline 12-week results from its Phase 2 study of UBX0101 in the third quarter of 2020. Consistent with prior guidance, 24-week results are also expected by the end of 2020. The company previously announced completion of enrollment of a Phase 2 study of UBX0101 in patients with moderate-to-severe osteoarthritis of the knee in February 2020. The study is randomized, double-blind, and placebo-controlled and will evaluate three doses of UBX0101 administered via a single intra-articular injection. UNITY is also conducting a Phase 1b study of UBX0101 in patients with moderate-to-severe OA of the knee. Enrollment in this study was completed in March 2020. The study is randomized, double-blind, and placebo-controlled and will explore the safety, tolerability and initial efficacy of a single 8.0 mg dose or multiple doses of UBX0101. Consistent with prior guidance, both 12- and 24-week results are expected in the second half of 2020.
Unity Biotechnology reports Q2 EPS (38c), consensus (51c) » 08:0707/3107/31/20
"We are pleased with…
"We are pleased with the progress we are making on advancing programs that target senescent cells to alter the course of diseases of aging," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "The second half of 2020 is a very important period for UNITY, with our topline 12-week Phase 2 data readout from the UBX0101 program in osteoarthritis expected in the third quarter, as well as the commencement of our initial clinical program in ophthalmology later in the second half of the year."
|Over a week ago|
Fly Intel: Top five analyst initiations » 10:0607/2807/28/20
BMY, BYND, SAIA, PODD, UBX
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bristol-Myers (BMY) initiated with an Outperform at Raymond James. 2. Beyond Meat (BYND) initiated with a Hold at Canaccord. 3. Saia (SAIA) initiated with a Neutral at BofA. 4. Insulet (PODD) initiated with an Overweight at Wells Fargo. 5. Unity Biotechnology (UBX) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Unity Biotechnology initiated with a Buy at Roth Capital » 16:0907/2707/27/20
Roth Capital analyst…
Roth Capital analyst Elemer Piros initiated coverage of Unity Biotechnology with a Buy rating and $35 price target. The company is developing treatments to extend healthspan by targeting diseases of aging, Piros tells investors in a research note. Unity established early clinical evidence with its lead drug UBX0101 in osteoarthritis and a single administration of the drug improved pain and function, says the analyst.
Arcus Biosciences names Bob Goeltz CFO » 16:1107/0707/07/20
RCUS, UBX, CTMX, GILD
Arcus Biosciences (RCUS)…
Arcus Biosciences (RCUS) announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Goeltz most recently served as Chief Financial Officer and Senior Vice President of UNITY Biotechnology (UBX) and immediately before that as Chief Financial Officer of CytomX Therapeutics (CTMX). "Following the recent announcement of our 10-year collaboration with Gilead (GILD) and successful $348 million financial offering, combined with our growing portfolio of programs, I am confident Bob will play an integral role in advancing Arcus through our next phase of growth towards commercialization and beyond," said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. "Bob's experience in navigating the strategic and operational decisions necessary to transition the opportunities derived from an intense, deep and innovative R&D effort through the commercialization process to broadly benefit patients will be central to Arcus's future success. With the potential to have three molecules in registrational studies in 2021, a prolific discovery team and a uniquely enabling and nascent alliance with Gilead, Bob joins Arcus at a seminal inflection point, with the opportunity to make Arcus's vision of creating, developing and commercializing innovative and curative therapies for cancer a reality."
|Over a month ago|
Unity Biotechnology names Lynne Sullivan as interim CFO » 17:0107/0607/06/20
UNITY Biotechnology (UBX)…
UNITY Biotechnology (UBX) announced that Bob Goeltz, CFO, will leave the company at the end of July 2020 to pursue a new opportunity. Effective August 1, 2020, Lynne Sullivan, former senior vice president of Biogen (BIIB), will become UNITY's interim CFO. Ms. Sullivan worked at Biogen for over 10 years, most recently serving as senior vice president of finance with global responsibility for corporate finance, financial planning and analysis and corporate tax.
Unity Biotechnology provides update on lead development programs » 16:1007/0107/01/20
Unity Biotechnology provided updates on its lead development programs. In February, Unity announced completion of enrollment of its Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with moderate-to-severe osteoarthritis of the knee. The study is randomized, double-blind, and placebo-controlled and will evaluate three doses of UBX0101 administered via a single intra-articular injection. UNITY expects to announce 12-week results from the study in Q3. Unity announced that it has completed investigational new drug, or IND-enabling studies with UBX1325, a senolytic, small molecule inhibitor of the anti-apoptotic Bcl-2 family member, Bcl-xL. Unity expects to file an IND for a Phase 1 safety study for UBX1325 and, assuming clinical sites are able to recruit and retain investigators and study staff and screen and enroll patients during the ongoing COVID 19 pandemic, to initiate a Phase 1 study in the second half of 2020 and obtain initial results from the study in 2021. The overall clinical program is directed at multiple age-related diseases of the eye, such as diabetic macular edema, diabetic retinopathy and age-related macular degeneration. In connection with the selection of UBX1325 as its lead molecule for the ophthalmology program, UNITY executed an amendment to an existing compound license agreement with Ascentage Pharma. The amended compound license agreement grants Unity exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China for UBX1325 in all non-oncology indications. Inside Greater China, Unity is obligated to commercialize UBX1325 through a joint venture with Ascentage Pharma. "The second half of 2020 will be an eventful period for UNITY, particularly for our cellular senescence programs for osteoarthritis and for age-related eye diseases," said Anirvan Ghosh, CEO of UNITY. "We expect important results from both our Phase 2 and Phase 1b studies of UBX0101 in patients with painful osteoarthritis of the knee where we see significant unmet need and the opportunity to develop a new class of therapeutic options with durable benefit. We are also excited to advance UBX1325 into clinical development in age-related eye diseases, such as diabetic macular edema and diabetic retinopathy, where senescent cell burden has been implicated and where clinicians and patients have a strong need for novel therapeutic options. UBX1325 is a Bcl-XL inhibitor and represents the second mechanism we are advancing to the clinic."
Goldman Sachs to hold a virtual conference » 08:4706/1106/11/20
HUM, DTIL, CHNG, ALKS, ALNY, HCAT, KLDO, ZEAL, GOSS, MRNA, ORTX, BMY, ADVM, BCYC, ESPR, PHAT, INSP, UBX, PHG, ATRA
41st Annual Global…
41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link